By targeting the GI pathway, Gelesis has the potential to transform how related chronic diseases are treated.

* Products are investigational and have not been cleared by the FDA for use in the United States.

Other pre-clinical programs: GS400 for IBD in pre-clinical stage.

* Products are investigational and have not been cleared by the FDA for use in the United States.

Other pre-clinical programs: GS400 for IBD in pre-clinical stage.

pipeline_water

PLENITY™

now FDA Cleared 

Stay up to date with Gelesis innovations